SCHEDULE: FMR LLC Boosts CytomX Therapeutics Stake to 14.6%

FMR LLC and Abigail P. Johnson report a 14.6% beneficial ownership stake in CytomX Therapeutics Inc. as of December 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 24,688,109 shares of CytomX Therapeutics Inc. common stock.
• This ownership represents 14.6% of the total outstanding common stock of CytomX Therapeutics Inc.
• FMR LLC holds sole voting and sole dispositive power over all 24,688,109 shares.
• Abigail P. Johnson, as Director, Chairman, and CEO of FMR LLC, is deemed to have sole dispositive power over the same 24,688,109 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• FMR LLC is classified as a parent holding company, with subsidiaries like FIAM LLC and Fidelity Management & Research Company LLC identified as investment advisers, and Fidelity Institutional Asset Management Trust Company as a bank.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant institutional stake from a reputable firm like FMR LLC can signal confidence in the company's value, although it is a routine disclosure of ownership.

Positives

• A significant institutional investor like FMR LLC holding a 14.6% stake can be viewed as a vote of confidence in CytomX Therapeutics Inc.'s long-term prospects.
• The filing explicitly states that the securities were acquired and are held in the ordinary course of business, indicating a passive investment rather than an activist intent to influence control.

Risks

• No specific risks related to CytomX Therapeutics Inc. are mentioned in this beneficial ownership filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance from CytomX Therapeutics Inc. or the reporting persons regarding the issuer's future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

StockSavvy.ai notes that FMR LLC, as a major institutional asset manager, frequently holds significant stakes across various public companies. Its substantial ownership in CytomX Therapeutics Inc. indicates its continued interest in the biotechnology sector, particularly in companies with potential for growth or strategic value, aligning with broader trends of institutional investment in life sciences.

Stakeholder Impact

• Shareholders: The significant stake held by FMR LLC could provide stability and potentially attract other institutional investors, positively impacting shareholder confidence.

Key Dates

Keywords

CytomX Therapeutics, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Biotechnology, Pharmaceuticals